John F Ward, M.D., FACS

Peer-Reviewed Articles

1. Urkmez A, Ward JF, Choi H, Troncoso P, Inguillo I, Gregg JR, Altok M, Demirel HC, Qiao W, Kang HC. Temporal Learning Curve of a Multidisciplinary Team for MRI-TRUS Fusion Prostate Biopsy. BJU Int 127(5):524-527, 2021. e-Pub 2021. PMID: 33340435.
2. Baiomy A, Jensen CT, Ward JF, Chasen BA, Ravizzini GC. Incidental 18F-Fluciclovine Uptake in a Desmoid Tumor Detected in a Patient Undergoing PET/CT Imaging for Prostate Cancer. Clin Nucl Med 46(4):355-357, 2021. e-Pub 2020. PMID: 33323736.
3. Liang Y, Raven F, Ward JF, Zhen S, Zhang S, Sun H, Miller SJ, Choi SH, Tanzi RE, Zhang C. Upregulation of Alzheimer's Disease Amyloid-β Protein Precursor in Astrocytes Both in vitro and in vivo. J Alzheimers Dis 76(3):1071-1082, 2020. PMID: 32597805.
4. Altok M, Kim B, Patel BB, Shih YT, Ward JF, McRae SE, Chapin BF, Pisters LL, Pettaway CA, Kim J, Demirel HC, Davis JW. Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research. Prostate Cancer Prostatic Dis. e-Pub 2018. PMID: 29988098.
5. Blanchard P, Davis JW, Frank SJ, Kim J, Pettaway CA, Pugh TJ, Pisters LL, Ward JF, Choi S, Chapin BF, Hoffman K, Navai N, Achim M, McGuire SE, Matin SF, Nguyen Q, Mahmood U, Graber WJ, Chen HC, Wang X, Kuban DA. Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int 121(4):540-548, 2018. e-Pub 2017. PMID: 28941030.
6. Reichard CA, Gregg JR, Achim MF, Aparicio AM, Pettaway CA, Pisters LL, Ward JF, Davis JW, Chapin BF. Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes. Eur Urol. e-Pub 2018. PMID: 29656854.
7. Basourakos SP, Davis JW, Chapin BF, Ward JF, Pettaway CA, Pisters LL, Navai N, Achim MF, Wang X, Chen HC, Choi S, Kuban D, Troncoso P, Hanash S, Thompson TC, Kim J. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int 121(1):69-76, 2018. e-Pub 2017. PMID: 28710901.
8. Raven F, Ward JF, Zoltowska KM, Wan Y, Bylykbashi E, Miller SJ, Shen X, Choi SH, Rynearson KD, Berezovska O, Wagner SL, Tanzi RE, Zhang C. Soluble Gamma-secretase Modulators Attenuate Alzheimer's β-amyloid Pathology and Induce Conformational Changes in Presenilin 1. EBioMedicine 24:93-101, 2017. e-Pub 2017. PMID: 28919280.
9. Li R, Petros FG, Davis CJ, Ward JF. Characterization of Glomus Tumors of the Kidney. Clin Genitourin Cancer. e-Pub 2017. PMID: 28967505.
10. Crouzet S, Blana A, Murat FJ, Pasticier G, Brown SCW, Conti GN, Ganzer R, Chapet O, Gelet A, Chaussy CG, Robertson CN, Thuroff S, Ward JF. Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients. BJU Int 119(6):896-904, 2017. e-Pub 2017. PMID: 28063191.
11. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23(5):551-555, 2017. e-Pub 2017. PMID: 28346412.
12. Pearce SM, Golan S, Gorin MA, Luckenbaugh AN, Williams SB, Ward JF, Montgomery JS, Hafez KS, Weizer AZ, Pierorazio PM, Allaf ME, Eggener SE. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. Eur Urol 71(3):476-482, 2017. e-Pub 2016. PMID: 27234998.
13. S. McRar, K. Sweetwood, K. Ahrar, S. Sabir, JF Ward III, J. Stafford, V. Kundra, H. Choi, S. Gupta, M. Wallace. Transgluteal MRI-guided prostate biopsy for patients with elevated prostate specific antigen and negative or equivocal transrectal ultrasound (TRUS) biopsy, 2017.
14. Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, Logothetis CJ, Pisters LL, Tu SM. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget 7(52):86280-86289, 2016. PMID: 27861143.
15. Williams SB, Ward JF. Re: Jan P. Radtke, Constantin Schwab, Maya B. Wolf, et al. Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.12.052. Eur Urol 70(3):e77-8, 2016. e-Pub 2016. PMID: 26988610.
16. Davis JW, Ward JF, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int 118(1):68-76, 2016. e-Pub 2015. PMID: 26059275.
17. Kenney PA, Nawaf CB, Mustafa M, Wen S, Wszolek MF, Pettaway CA, Ward JF, Davis JW, Pisters LL. Robotic-assisted laparoscopic versus open salvage radical prostatectomy following radiotherapy. Can J Urol 23(3):8271-7, 2016. PMID: 27347619.
18. Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karam JA, Ward JF, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, Yeung SC, Lin SH, Logothetis CJ, Pisters LL. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer 122(12):1836-43, 2016. e-Pub 2016. PMID: 27018785.
19. Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Stephenson A, Li Ning Tapia EM, Efstathiou E, Wang X, Do KA, Lee JJ, Gorlov IP, Vornik LA, Hoque AM, Prokhorova IN, Parnes HL, Lippman SM, Thompson IM, Brown PH, Logothetis CJ, Troncoso P. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine 7:85-93, 2016. e-Pub 2016. PMID: 27322462.
20. Parker PA, Davis JW, Latini DM, Baum G, Wang X, Ward JF, Kuban D, Frank SJ, Lee AK, Logothetis CJ, Kim J. Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int 117(3):469-77, 2016. e-Pub 2015. PMID: 25714186.
21. Mustafa M, Delacroix S, Ward JF, Pisters L. The feasibility and safety of repeat cryosurgical ablation of localized prostate cancer. World J Surg Oncol 13(1):340, 2015. e-Pub 2015. PMID: 26691335.
22. Ward JF, Eggener SE. Active surveillance monitoring: the role of novel biomarkers and imaging. Asian J Androl 17(6):882-4; discussion 883, 2015. e-Pub 2015. PMID: 26112488.
23. van den Bos W, Muller BG, de Bruin DM, de Castro Abreu AL, Chaussy C, Coleman JA, Finelli A, Gill IS, Gross ME, Jenniskens SF, Kahmann F, Laguna-Pes MP, Rastinehad AR, Simmons LA, Sulser T, Villers A, Ward JF, de la Rosette JJ. Salvage ablative therapy in prostate cancer: International multidisciplinary consensus on trial design. Urol Oncol 33(11):495.e1-7, 2015. e-Pub 2015. PMID: 26231310.
24. Williams SB, Davis JW, Wang X, Achim MF, Zurita-Saavedra A, Matin SF, Pisters LL, Ward JF, Pettaway CA, Chapin BF. Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien System. Clin Genitourin Cancer. e-Pub 2015. PMID: 26558524.
25. Zurita AJ, Pisters LL, Wang X, Troncoso P, Dieringer P, Ward JF, Davis JW, Pettaway CA, Logothetis CJ, Pagliaro LC. Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer. Prostate Cancer Prostatic Dis 18(3):276-80, 2015. e-Pub 2015. PMID: 26171883.
26. Valerio M, Emberton M, Barret E, Eberli D, Eggener SE, Ehdaie B, Jichlinski P, Ward JF, Ahmed HU. Health technology assessment in evolution - focal therapy in localised prostate cancer. Expert Rev Anticancer Ther 14(11):1359-67, 2014. e-Pub 2014. PMID: 24965212.
27. Subbiah V, Meric-Bernstam F, Mills GB, Shaw KR, Bailey AM, Rao P, Ward JF, Pagliaro LC. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. J Hematol Oncol 7:52, 2014. e-Pub 2014. PMID: 25085632.
28. Madsen LT, Kuban DA, Choi S, Davis JW, Kim J, Lee AK, Domain D, Levy L, Pisters LL, Pettaway CA, Ward JF, Logothetis C, Hoffman KE. Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic. J Natl Compr Canc Netw 12(7):993-8, 2014. PMID: 24994920.
29. van den Bos W, Muller BG, Ahmed H, Bangma CH, Barret E, Crouzet S, Eggener SE, Gill IS, Joniau S, Kovacs G, Pahernik S, de la Rosette JJ, Rouvière O, Salomon G, Ward JF, Scardino PT. Focal Therapy in Prostate Cancer: International Multidisciplinary Consensus on Trial Design. Eur Urol 65(6):1078-83, 2014. e-Pub 2014. PMID: 24444476.
30. Reis LO, Billis A, Zequi SC, Tobias-Machado M, Viana P, Cerqueira M, Ward JF. Supporting prostate cancer focal therapy: a multidisciplinary International Consensus of Experts ("ICE"). Aging Male 17(2):66-71, 2014. e-Pub 2014. PMID: 24597940.
31. van den Bos W, Muller BG, Ahmed H, Bangma CH, Barret E, Crouzet S, Eggener SE, Gill IS, Joniau S, Kovacs G, Pahernik S, de la Rosette JJ, Rouvière O, Salomon G, Ward JF, Scardino PT. Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. Eur Urol 6(65):1078-83, 2014.
32. Ward JF, DiBlasio CJ, Williams C, Given R, Jones JS. Cryoablation for locally advanced clinical stage T3 prostate cancer: a report from the Cryo-On-Line Database (COLD) Registry. BJU Int 113(5):714-8, 2014. e-Pub 2014. PMID: 24112776.
33. Gittelman MC, Hertzman B, Bailen J, Williams T, Koziol I, Henderson RJ, Efros M, Bidair M, Ward JF. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol 190(1):64-9, 2013. e-Pub 2013. PMID: 23416644.
34. Matin SF, Cormier JN, Ward JF, Pisters LL, Wood CG, Dinney CP, Royal RE, Huang X, Pettaway CA. Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with penile carcinoma. BJU Int 111(7):1068-74, 2013. e-Pub 2013. PMID: 23551693.
35. Leibovici D, Chiong E, Pisters LL, Guo CC, Ward JF, Andino L, Prokhorova IN, Troncoso P. Pathological characteristics of prostate cancer recurrence after radiation therapy: implications for focal salvage therapy. J Urol 188(1):98-102, 2012. e-Pub 2012. PMID: 22578724.
36. Pisters PW, Pettaway CA, Liu P, Matin SF, Ward JF, Leibovici D. Is transureteroureterostomy performed during multi-organ resection for non-urothelial malignancy safe and effective?. J Surg Oncol 106(1):62-5, 2012. e-Pub 2012. PMID: 22259198.
37. Liu H, Zhang T, Chen R, McConkey DJ, Ward JF, Curley SA. Multiple Kinase Pathways Involved in the Different De Novo Sensitivity of Pancreatic Cancer Cell Lines to 17-AAG. J Surg Res 176(1):147-53, 2012. e-Pub 2011. PMID: 22099584.
38. Ward JF, Jones JS. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int 109(11):1648-54, 2012. e-Pub 2011. PMID: 22035200.
39. Ward JF, Jones S. Organ-sparing (Focal) Cryotherapy for Localized Prostate Cancer: A Report from the National Cyro On-Line Data (Cold) Registry. BJU Int 109(11):1648-54, 2012.
40. Ganzer R, Robertson CN, Ward JF, Brown SC, Conti GN, Murat FJ, Pasticier G, Rebillard X, Thuroff S, Wieland WF, Blana A. Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria - analysis from the @-Registry. BJU Int 108(8 Pt 2):E196-201, 2011. e-Pub 2011. PMID: 21332907.
41. Dhar N, Ward JF, Cher ML, Jones JS. Primary full-gland prostate cryoablation in older men (> age of 75 years): results from 860 patients tracked with the COLD Registry. BJU Int 108(4):508-12, 2011. e-Pub 2011. PMID: 21722288.
42. Asher GW, Archer JA, Ward JF, Scott IC, Littlejohn RP. Effect of melatonin implants on the incidence and timing of puberty in female red deer (Cervus elaphus). Anim Reprod Sci 123(3-4):202-9, 2011. e-Pub 2010. PMID: 21190800.
43. Auprich M, Chun FK, Ward JF, Pummer K, Babaian R, Augustin H, Luger F, Gutschi S, Budäus L, Fisch M, Huland H, Graefen M, Haese A. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol 59(1):96-105, 2011. e-Pub 2010. PMID: 20980098.
44. Liu H, Zhang T, Chen R, McConkey DJ, Ward JF, Curley SA. Multiple kinase pathways involved in the diffeent de novo sensitivity of pancreatic cancer cell lines to 17-AAG. J Surg Res 176(1):147-53, 2011.
45. Stafford RJ, Shetty A, Elliott AM, Klumpp SA, McNichols RJ, Gowda A, Hazle JD, Ward JF. Magnetic Resonance-Guided Focal Laser-Induced Interstitial Thermal Therapy in a Canine Prostate Model. J Urol 184(4):1514 - 1520, 2010. e-Pub 2010. PMID: 20727549.
46. Stafford RJ, Shteey A, Elliott AM, Klump SA, McNichols RJ, Gowda A, Hazle JD, Ward JF. Magnetic resonanace guided, focal laser induced interstitial thermal therapy in a canine prostate model. J Urol 184(4):1514-20, 2010.
47. Ward JF, Jones JS. Classification System: Organ Preserving Treatment for Prostate Cancer. Urology 75(6):1258-60, 2010. e-Pub 2010. PMID: 20080292.
48. Davis JW, Kim J, Ward JF, Wang X, Nakanishi H, Babaian RJ, Troncoso P. Radical prostatectomy findings in patients predicted to have low-volume/low-grade prostate cancer diagnosed by extended-core biopsies: an analysis of volume and zonal distribution of tumour foci. BJU Int 105(10):1386-91, 2010. e-Pub 2009. PMID: 19888979.
49. Ward JF, Jones JS. Classification system: organ preserving treatment for prostate cancer. Urology 75(6):1258-60, 2010.
50. Blana A, Brown SC, Chaussy C, Conti GN, Eastham JA, Ganzer R, Murat FJ, Pasticier G, Rebillard X, Rewcastle JC, Robertson CN, Thuroff S, Ward JF. High-Intensity Focused Ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int 104(8):1058-62, 2009. e-Pub 2009. PMID: 19388986.
51. Pisters LL, Leibovici D, Blute M, Zincke H, Sebo TJ, Slezak JM, Izawa J, Ward JF, Scott SM, Madsen L, Spiess PE, Leibovich BC. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol 182(2):517-52, 2009. e-Pub 2009. PMID: 19524984.
52. Ward JF, Nakanishi H, Pisters L, Babaian RJ, Troncoso P. Cancer Ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy. BJU Int 104(4):490-7, 2009. e-Pub 2009. PMID: 19220260.
53. Ward JF, Margulis V. Continuous improvement of TNM staging system for bladder cancer. Cancer 115:704-705, 2009.
54. Chen H, Liakou CI, Kamat AM, Pettaway CA, Ward JF, Tang DN, Sun J, Jungbluth AA, Troncoso P, Logothetis C, Sharma P. Anti-CTLA-4 therapy results in higher CD4(+)LCOS(hi) T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci USA 106:2729-2734, 2009.
55. Ward JF, Margulis V. Continous improvement of TNM staging system for bladder cancer. Cancer 115(4):704-5, 2009. PMID: 19117038.
56. Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, Sun J, Jungbluth AA, Troncoso P, Logothetis C, Sharma P. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A 106(8):2729-34, 2009. e-Pub 2009. PMID: 19202079.
57. Ward JF, Nakanishi H, Babaian RJ, Troncoso P. In-field/out-field prostate cancer foci: multifocality and considerations for the application of focal prostate therapy. Journal of Urology 179(4):493, 2008.
58. Davis JW, Troncoso P, Ward JF, et al.. Active Surveillance for clinically localized prostate cancer in the era of technology: Introduction of a prospective protocol into a high volume tertiary referral centre. European Urology Supplements 3:234, 2008.
59. Ward JF. Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?. Nat Clin Pract Urol 3/6(6):310-1, 2006. PMID: 16763642.
60. Ward JF. Salvage Radiotherapy for PSA-only Recurrence. The American Journal of Urology Review 3:366-374, 2005. e-Pub 2005.
61. Ward JF, Moul JW. Treating the biochemical recurrence of prostate cancer after definitive primary therapy. Clin Prostate Cancer 4/1(1):38-44, 2005. PMID: 15992460.
62. Ward JF, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. Radical Prostatectomy for clinically advanced (ct3) prostate cancer in the PSA era: 15-year outcomes. J Urol 173(4):224-224, 2005.
63. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 95/6(6):751-6, 2005. PMID: 15794776.
64. Ward JF, Sebo TJ, Blute ML, Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol 173/4(4):1156-60, 2005. PMID: 15758726.
65. Ward JF, Moul JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol 2/4(4):174-82, 2005. PMID: 16474760.
66. Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Blute ML. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 172/6 Pt 1(6 Pt 1):2244-8, 2004. PMID: 15538240.
67. Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Myers RP, Blute ML. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol 172/4 Pt 1(4 Pt 1):1328-32, 2004. PMID: 15371834.
68. Ward JF, Bartsch G, Sebo TJ, Pinnggera GM, Blute ML, Zincke H. Pathologic characterization of prostate cancers with very low serum prostate specific antigen (0-2 ng/mL) incidental to cystoprostatectomy: is PSA a useful indicator of clinical significance?. Urol Oncol 22/1:40-7, 2004.
69. Ward JF, Bartsch G, Sebo TJ, Pinggera GM, Blute ML, Zincke H. Pathologic characterization of prostate cancers with a very low serum prostate specific antigen (0-2 ng/mL) incidental to cystoprostatectomy: is PSA a useful indicator of clinical significance?. Urol Oncol 22(1):40-7, 2004. PMID: 14969803.
70. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 170(5):1872-6, 2003. PMID: 14532796.
71. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatecomy. J Urol 170/5:1872-6, 2003.
72. Ward JF, Zincke H. Radical prostatectomy for the patient with locally advanced prostate cancer. Curr Urol Rep 4/3(3):196-204, 2003. PMID: 12756082.
73. Ward JF, Zincke H, Sebo TJ, Blute ML. Salvage Surgery for radiorecurrent prostate cancer: Outcomes and Complications from a 30-year experience. J Urol 169(4):397, 2003.
74. Ward JF, Zincke, Slezak J, Bergstralh EJ, Blute Ml. Calculated Prostate Specific Antigen Doubling Time Subsequent to Radical Prostatectomy as a Predictor of Response to Salvage Pelvic Radiotherapy. J Urol 169(4):278, 2003.
75. Ward JF, Blute JL, Slezak J, Bergstralh EJ, Zincke H. Long-Term (>5 years) biological pattern of clinically recurrent prostate cancer subsequent to radical prostatectomy. Journal of Urology 169(4):71-71, 2003.
76. Ward JF, Blute ML, Bergstralh EJ, Slezak J, Zincke. The Impact of Nerve Sparing Versus Wide Local Excision on Margin Positive Rates During Radical Prostatectomy. Journal of Urology 169(4):180-180, 2003.
77. Gray Sears CL, Ward JF, Sears ST, Puckett MF, Kane CJ, Amling CL. Prospective comparison of computerized tomography and excretory urography in the initial evaluation of asymptomatic microhematuria. J Urol 168(6):2457-60, 2002. PMID: 12441939.
78. Zincke H, Ward JF. Outcome of Laparoscope Radical and Open Partial Nephrectomy for the Sporadic 4cm. or Less Renal Tumor with a Normal Contralateral Kidney. J Urol 168(4):1359-1360, 2002.
79. Ward JF, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma. J Urol 168/1(1):56-60, 2002. PMID: 12050492.
80. Ward JF, Pinggera GM, Zincke H, Bartsch G. Clinical and Pathological Characterization of Non-Palpable Prostate Cancer in a very low PSA range (0-2ng/ml). Journal of Urology 167(4):71-72, 2002.
81. Kane CJ, Tarman GJ, Summerton DJ, Buchmann CE, Ward JF, O'Reilly KJ, Ruiz H, Thrasher JB, Zorn B, Smith C, Morey AF. Multi-institutional experience with buccal mucosa onlay urethroplasty for bulbar urethral reconstruction. J Urol 167/3(3):1314-7, 2002. PMID: 11832721.
82. Borboroglu PG, Amling CL, Schenkman NS, Monga M, Ward JF, Piper NY, Bishoff JT, Kane CJ. Ureteral stenting after ureteroscopy for distal ureteral calculi: a multi-institutional prospective randomized controlled study assessing pain, outcomes and complications. J Urol 166/5(5):1651-7, 2001. PMID: 11586195.
83. Amling CL, Kane CJ, Riffenburgh RH, Ward JF, Roberts JL, Lance RS, Friedrichs PA, Moul JW. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology 58/5(5):723-8, 2001. PMID: 11711349.
84. Ward JF, Moquin RR, Maurer ST. Expanding the differential diagnosis of the acute scrotum: ventriculoperitoneal shunt herniation. Urology 58(2):281, 2001. PMID: 11489724.
85. Ward JF, Mouquin RR, Maurer ST. Expanding the differnetial diagnosis of the acute scrotum: ventriculoperitoneal shunt herniation. Urology 58/2:281, 2001.
86. Ward JF, Sands JP, Nowacki M, Amling CL. Malignant cytological washings from prostate specimens: an independent predictor of biochemical progression after radical prostatectomy. J Urol 165/2(2):469-73, 2001. PMID: 11176398.
87. Ward JF, Cilento BG, Kaplan GW, Velling TE, Puckett M, Stock J. The ultrasonic description of postpubertal testicles in men who have undergone prepubertal orchiopexy for cryptorchidism. J Urol 163/5(5):1448/50, 2000. PMID: 10751855.
88. Borboroglu PG, Kane CJ, Ward JF, Roberts JL, Sands JP. Immediate and postoperative complications of transurethral prostatectomy in the 1990's. J Urol 162/4(4):1307-10, 1999. PMID: 10492185.
89. Ward JF, Johnstone PA, Kane CJ. Free-to-total prostate-specific antigen ratios 18-24 months following external beam radiation for adenocarcinoma of the prostate. J Surg Oncol 70/2(2):91-4, 1999. PMID: 10084650.
90. Gray C, Ward JF, Sands JP. Syncope from increased ventricular response in atrial fibrillation during voiding: a new indication for surgical management in benign prostatic hyperplasia. J Urol 161/2(2):606-7, 1999. PMID: 9915461.
91. Ward JF, Kaplan GW, Mevorach R, Stock JA, Cilento BG. Refined microscopic urinalysis for red blood cell morphology in the evaluation of asymptomatic microscopic hematuria in a pediatric population. J Urol 160/4(4):1492-5, 1998. PMID: 9751402.
92. Ward JF, Friedlander SF, Kaplan GW. Hemangioma presenting as an ulceration of the scrotum. J Urol 160/1(1):182-3, 1998. PMID: 9628647.
93. Gentle DL, Stoller ML, Jarrett TW, Ward JF, Geib KS, Wood AF. Protease inhibitor-induced urolithiasis. Urology 50/4(4):508-11, 1997. PMID: 9338723.
94. Ward JF, Nowacki M, Sands JP, Conner RJ, Huisman TK. Malignant cytological washings from radical prostatectomy specimens: a possible mechanism for local recurrence of prostate cancer following surgical treatment of organ confined disease. J Urol 156/4(4):1381-4: discussion 1384-5, 1996. PMID: 8808876.
95. Ward JF, Nowacki M, Sands JP, Conner RJ, Huisman TK. Malignant cytological washing from radical prostatectomy specimens: a possible mechanism for local recurrent of prosate cancer following surgical treatment of organ confined disease. J Urol 156(4):1381-4, 1996.
96. Duff DW, Fitzgerald D, Kullman D, Lipke DW, Ward J, Olson KR. Blood Volume and Red Cell Space in Tissues of the Rainbow Trout, Salmo Gairdneri. Comp Biochem Physiol A Comp Physiol 87(2):393-398, 1987. PMID: 2886280.
97. Duff DW, Olson KR, Ward JF. Vascular and Renal Responses to Atrial Natriuretic Factor and Heart Extracts. American Journal of Physicology 251:R639-642, 1986.

Invited Articles

1. Ward JF, Pisters LL. Considerations for patient selection for focal therapy. Ther Adv Urol 5(6):330-7, 2013. PMID: 24294291.
2. Blana A, Robertson CN, Brown SC, Chaussy C, Crouzet S, Gelet A, Conti GN, Ganzer R, Pasticier G, Thuroff S, Ward JF. Complete high-intensity focused ultrasound in prostate cancer: outcome from the @-Registry. Prostate Cancer Prostatic Dis 15(3):256-9, 2012. e-Pub 2012. PMID: 22487909.
3. Shih YC, Ward JF, Pettaway CA, Xu Y, Matin SF, Davis JW, Thompson BP, Elting LS. Comparative effectiveness, cost, and utilization of radical prostatectomy among young men within managed care insurance plans. Value Health 15(2):367-75, 2012. e-Pub 2011. PMID: 22433769.
4. Ward JF, Rewcastle JC, Ukimura O, Gill IS. Focal Therapy for the Treatment of Localized Prostate Cancer: A Potential Therapeutic Paradigm Shift Awaiting Better Imaging. Curr Opin Urol 22(2):104-8, 2012. PMID: 22273756.
5. Shih YC, Ward JF, Pettaway CA. Comparative effectiveness, cost, and utilization of radical prostatectomy among young men within managed care insurance plans. Value Health 15(2):367-75, 2012.
6. Ward JF. Clinical Stage 3 Prostate Cancer. UpToDate, 2011.
7. Ward JF. High-intensity focused ultrasound for therapeutic tissue ablation in surgical oncology. Surg Oncol Clin N Am 20(2):389-407, 2011. PMID: 21377590.
8. Ward JF. Prostate cancer: HIFU is effective, but associated morbidity still remains unclear. Nat Rev Urol 7(11):597-8, 2010. PMID: 21068758.
9. Ward JF. Contemporary Outcomes of Focal Therapy in Prostate Cancer: What do we know so far?. World J Urol 28(5):593-7, 2010. e-Pub 2010. PMID: 20680294.
10. Delacroix SE, Ward JF. Prostate cancer multifocality: impact on cancer biology and treatment recommendations. Panminerva Med 52(3):209-16, 2010. PMID: 21045777.
11. Ward JF. Contemporary outcomes of focal therapy in prostate cancer: what do we know so far. World J Urol 28(5):593-7, 2010.
12. Ward J, Vogelzang N, Davis B. Management of Locally Advanced Prostate Cancer I. Up To Date Journal 14(2), 2009.
13. Ward J, Vogelzang N, Davis B. Management of Locally Advanced Prostate Cancer II. Up To Date Journal 14(2), 2009.
14. Ward J, Vogelzang N, Davis B. Management of Locally Advanced Prostate Cancer III. Up To Date Journal 14(2), 2009.
15. Ward JF, Pagliaro LC, Pisters LL. Salvage Therapy for Radiorecurrent Prostate Cancer. Curr Probl Cancer 32(6):242-271, 2008. PMID: 19064119.
16. Ward JF, Vogelzang N, Davis B. Management of locally advanced (T3) prostate cancer II. UpToDate, 2007.
17. Moul JW, Ward JF. Management of the patient with a rising PSA alone. Hematol Oncol Clin North Am 20/4(4):897-908, 2006. PMID: 16861121.
18. Freedland SJ, Ward JF. PSA recurrence of prostate cancer--Update 2006. Issues in Urology 18/3:109-18, 2006.
19. Ward JF. Salvage Radiotherapy for PSA-Only Recurrence. The American Journal of Urology Review 3/8, 2005.
20. Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. Curr Opin Urol 15(3):187-95, 2005. PMID: 15815196.
21. Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer. Curr Opin Urol 15/3(3):181-6, 2005. PMID: 15815195.
22. Young CY, Jatoi A, Ward JF, Blute ML. The effects of dietary factors on the androgen receptor and related cellular factors in prostate cancer. Curr Med Chem 11/7(7):909-23, 2004. PMID: 15078173.
23. Ward JF, Blute ML. Chemoprevention of prostate cancer. Expert Rev Anticancer Ther 3/2(2):203-14, 2003. PMID: 12722880.
24. Ward JF, Amling CL, McKusick MA. The Use of Percutaneous Transcatheter Embolization in Urology. AUA Update Series 22/Lesson 39:309-320, 2003.
25. Ward JF, Velling TE. Transcatheter therapeutic embolization of genitourinary pathology. Reviews in Urology 2:236-245, 2000.
26. Ward JF, Gray C. Increased Ventricular Response in Atrial Fibrillation During Voiding: A New Indication for Surgical Management of Bening Prostatic Hypertrophy. Cardiology Review Series 2100:10-11, 2000.
27. Ward JF, Velling TE. Transcatheter Therapeutic Embolization of Genitourinary Pathology. Rev Urol 2(4):236-245, 2000. PMID: 16985760.

Manuals, Teaching Aids, Other Teaching Publications

1. Ward JF, Curley S, Lu X. Targeting of prostate cancer cells with gold nanparticles and non-invasive/minimally invasive RF treatment. American Association for Cancer Research: Orlando, FL, 2011.
2. Ward JF, Blute ML. Mayo Clinic on Prostate Health. Mayo Clinic Health Information: Rochester, MN, 2003.

Other Articles

1. Hoseman S, Ward JF, Kuban DA Organ-Confined Prostate Cancer. OncoLog 54(4):4-6, 2009.
2. Ward JF Prostate Cancer, PSA, and questions that can only be answered by clinical trials-The Moul/Banez/Freedland Article Reviewed. Oncology-New York 12:1452, 2007.

Editorials

1. Ward JF. Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur Urol 57(3):444-5, 2010. PMID: 19303198.
2. Ward JF, Vogelzang N. Management of locally advanced (T3) prostate cancer. UpToDate Journal, 2009.
3. Margulis V, Ward JF. A Comparison of American Joint Committee on Cancer Pathologic Stage T3a versus T3b urothelial carcinoma: Analysis of patient outcomes. CANCER 115(4):704-5, 2009.
4. Ward JF. Salvage radical prostatectomy: Quality of Life outcomes and long-term oncologic control of radiorecurrent prostate cancer. Journal of Urology 176(5):2025-2032 2032 A, 2006.
5. Ward JF. Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. Cancer/Nature Clinical Practice Urology, Summer 2006 106:63-67, 2006.
6. Ward JF. Delay of Radical Prostatectomy and Risk of Biochemical progression in men with low Risk Prostate Cancer. J Urol 175(4):1298-1303; Editorial Comments 1303A, 2006.
7. Ward JF. Comments on "single-strand-specific radiosensitization by bromodeooxyuridine" by Cecchini et al. Radiat Res 164(3):341-2, Sep 2005, 2005.
8. Ward JF, Zincke H. Radical Cystectomy with Preservation of Sexual Function and Urinary Continence: Description of A New Technique. International Brazilian Journal of Urology 29/3, 2003.
9. Ward JF, Zincke H. Outcome of Laparoscopic Radical and Open Partial Nephrectomy for the Sporadic 4 Cm. or Less Renal Tumor with a Normal Contralateral Kidney. J Urol 168/4 Pt 1:1356-9; Editorial Comments 1359-60, 2002.

Abstracts

1. Thueroff S, Chaussy ZC, Baco E, Berge V, Blana A, Crouzet S, Pasticier G, Paulesu A, Robertson CN, Ward JF. High Intensity Focused Ultrasound in Prostate Cancer: Multicentric, Long Term Retreatment Rate Decrease. J Urol:MP46-11A, 2014.
2. van den Box, W, Muller BG, Ahmed H, Bangma CH,Barret E, Crouzet S, Eggener SE, Gill IS, Joniau S, Kovacs G, Pahernik S, de la Rosette JJ, Rouviere O, Salomon G, Ward JF, Scardino PT. Focal Therapy in Prostate Cancer: International Multidisciplinary Consensus on Trial Design. 29th Annual EAU Congress, 2014.
3. Sharjeel, S., Choi, C., Ward, JF, III, Ahrar, K., McRae, SE. Transgluteal MR-guided prostate biopsy: results of a freehand technique in a closed 1.5t MRI. Journal of Vascular and Interventional Radiology, 2013.
4. Sabir SH, Choi H, Ward JF, Wallace M, McRae S. Transgluteal MR-guided Prostate Biopsy: Results of a Freehand Technique in a Closed 1.5T MRI. 2013 Proceedings of the Annual Society of Internventional Radiology:418A, 2013.
5. Gao J, Thall PF, Sun JJ, Ward JF, Rao P, Troncoso P, Araujo J, Ng Tan DS, Chen H, Wen S, Sharma P. Combination therapy with anti-CTLA-4 plus leuprolide acetate in the pre-surgical setting of patients with regional, high-risk prostate cancer. 2012 Proceedings of the American Association for Cancer Research:4388A, 2012.
6. Ward JF, Curley S, Lu X. Targeting of prostate cancer cells with gold nanoparticles and non-invasive/minimally invasive RF treatment. American Association for Cancer Research, 2011.
7. Zurita AJ, Ward JF, Araju C, Pettaway CA, Dieringer P, Wang X, Troncoso P, Logothetis CR. Neoadjuvant trial of sunitinib malate and androgen ablation (ADT) in patients w/ localized cancer (PCa at high risk for recurrence. ASCO 2011 Genitourinary Cancers Symposium, 2011.
8. Ward JF, Graefen M, Huland H, Kollermann J, Sauter G, Wang XM, Haese A, Troncoso P, Babaian RJ, Chun FKH. PCA3 score based nomogram to predict low-volume/low-grade prostate cancer in radical prostatectomy specimens. Journal of Urology 181:155, 2009.
9. Ward JF, Brown SCW, Chaussy C, Conti GN, Eastham JA, Ganzer R, Gelet A, Murat J, Rebillard X, Rewcastle JC, Robertson CN, Thueroff S, Blana A. Correlation of biochemical events and clinical failure following high intensity focused ultrasound of the prostate: The Stuttgart Definition. Journal of Urology 181:636A, 2009.
10. Dhar N, Cher ML, Pisters LL, Ward JF, Jones JS. Primary full gland prostate cyroablation: Updated results from 3209 patients tracked with the COLD registry. Journal of Urology 181:631A, 2009.
11. Dhar N, Cher ML, Levy DA, Pisters LL, Ward JF, Jones JS. Salvage prostate cryoablation: Updated results from 445 patients tracked with the COLD registry. Journal of Urology 181:1976A, 2009.
12. Davis JW, Troncoso P, Ward JF, Pettaway CA, Pisters LL, Kuban D, Brown V, Logothetis C, Kim J. Active surveillance for localized prostate cancer - A prospeective protocol. Journal of Urology 181:494A, 2009.
13. Chun FKJ, Ward JF, Huland H, Kollermann J, Sauter G, Graefen M, Troncoso P, Babaian RJ, Haese A. Prostate Cancer Antigen 3 (PCA3) shows significant association to prostate cancer volume but no correlation to total prostate volume or serum prostate specific antigen. Journal of Urology 181:2127A, 2009.
14. Blana A, Borwn SCW, Chaussy C, Conti GN, Eastham JA, Ganzer R, Murat FJ, Rebillard X, Rewcastle JC, Robertson CN, Thueroff S, Ward Jf, Gelet A. Primary prostate HIFU without pretreatment hormone therapy: Biochemical survival of 468 patients tracked with the @-registry. Journal of Urology 181:635A, 2009.
15. Ward JF, Chun F, Fraefen M, Huland H, Kollermann J, Sauter G, Babaian RJ, Haese A. Prostate Cancer Antigen 3 (PCa3) is an independent and significant predictor for pathologically insignificant Prostate Cancer (PCa) in men undergoing radical prostatectomy. European Urology Supplements, 2009.
16. Biana A, Brown SCW, Chaussy C, Conti GN, Eastham JA, Ganzer R, Gelet R, Murat FJ, Rebilliard S. RoRobertson CN, Thueroff S, Ward JF, Rewcastle JC. Defining biochemical failure following high intensity focused ultrasound of the prostate: The Stuttgart Definition. European Urology Supplements, 2009.
17. Blana A, Brown SCW, Chaussy C, Conti GN, Eastham JA, Ganzer R, Murat FJ, Rebilliard X, Rewcastle JC, Robertson CN, Thueroff S, Ward JF, Gelet A.. Primary prostate HIFU without pretreatment hormone therapy: Biochemical survival of 763 patients tracked with the @-registry. European Urology Supplements, 2009.
18. Chun F, Ward JF, Huland H, Kollerman J, Sauter G, Graefen M, Babain RJ, Haese A.. Prostate cancer antigen 3 (PCa3) shows significant association to prostate cancer volume (PCaV) but no correlation to total prostate volume or serum prostate specific antigen (PSA) and separates patholologically insignificant from significant prostate cancer (PCa) in men undergoing radical prostatectomy. European Urology Supplements, 2009.
19. Parker PA, Latini DM, Ward JF, Pettaway CA, Pisters LL, Matin SF, Frank SJ, Brown V, Kuban DA, Logothetis CJ, Kim J, Davis JW. Associations Between Uncertainty, Anxiety, and Quality of Life in Men with Prostate Cancer on Active Surveillance. Annals of Behavioral Medicine (Suppl):37A, 2009.
20. Ward JF, Nakanishi H, Babaian RJ, Troncoso P. In-Field/Out Field Prostate Cancer Foci: Multifocality and Considerations for the Application of Focal Prostate Therapy. Duke Abstracts -1st Int'l Workshop on Focal Therapy & Imaging of Prostate Cancer, 2009.
21. Ward JF. Evaluation of Regionally Ablative Templates (Hockey Stick and Hemiprostate) Applied to Prostatectomy Specimens From Men with Unilaterally Positive Biopsies. 2008 American Radium Society Annual Meeting, 2008.
22. Troncoso P, Davis JD, Ward JF, Wang X, Babaian RJ, Kim J. Prostatectomy findings in patients considered potential candidates for active surveillance. Modern Pathology 21:185A, 2008.
23. Troncoso P, Davis JW, Ward JF, Wang X, Babaian RJ, Kim J. Radical Prostatectomy findingd in patients considered potential candidates for active surveillance. Laboratory Investigation 88:185A, 2008.
24. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical Prostatectomy for Clinically Advanced (cT3) Prostate Cancer in the PSA Era: 15-Year Outcomes. Journal of Urology:42A, 2005.
25. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical Prostatectomy for Clinically Advanced (cT3) Prostate Cancer in the PSA Era: 15-Year Outcomes. Kimbrough Urologic Meeting (#96):96A, 2005.
26. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical Prostatectomy for Clinically Advanced (cT3) Prostate Cancer in the PSA Era: 15-Year Outcomes. Young Urologic Oncologists Meeting, 2004.
27. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical Prostatectomy for Clinically Advanced (cT3) Prostate Cancer in the PSA Era: 15-Year Outcomes. Society of Urologic Oncology Meeting (#44):44A, 2004.
28. Ward, JF. Calculated prostate specific antigen doubling time subsequent to radical prostatecomy as a predictor of response to salvage pelvic radiotherapy. Journal of Urology, 2003.
29. Ward JF. Salvage Surgery for Radiorecurrent Prostat Cancer: Outcomes and Complications from a 30 Year Experience. Journal of Urology:1484A, 2003.
30. Ward JF. Long-term (>5 years) biological pattern of clinically recurrent prostate cancer subsequent to radical prostatectomy. Journal of Urology:275A, 2003.
31. Ward JF. Does DNA ploidy and nuclear morphometry add to outcome prediction models for patients with completely resected pT1 conventional cell carcinoma of the kidney?. Journal of Urology:1015A, 2003.
32. Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Blute ML. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. Association 101st Meeting (#1079):1079A, 2003.
33. Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Myers RP, Blute ML. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. Journal of Urology 693A, 2003.
34. Ward JF. Long Term (>5 years) biological pattern of clinically recurrent prostate cancer subsequent to radical prostatectomy. Society of Urologic Oncologists, 3rd Annual Meeting, 2002.
35. Ward JF. Prostate Cancer imaging in Murine Model using Carbon-11 Labeled Choline and Acetate. Academy of Molecular Imaging (#136):136A, 2002.
36. Ward JF. Salvage Surgery for Radiorecurrent Prostat Cancer: Outcomes and Complications from a 30 Year Experience. North Central Section of the AUA 76th Meeting:30A, 2002.
37. Ward JF. Prostate Cancer imaging in Murine Model Using Carbon-11 Labeled Choline and Acetate. Molecular Imaging and Biology 4/4 Supplement 1:35A, 2002.
38. Ward JF. Clinical and Pathologic Characterization of Non-palpable Prostat Cancer in a very low PSA Range (0-2ng/ml). Journal of Urology:283A, 2002.
39. Ward JF. Expanding the Differential Diagnosis of the Acute Scrotum: Ventriculoperitoneal Shunt Herniation. Kimbrough Urological Seminar (#88):88A, 2001.

Book Chapters

1. Ward JF. Focal Cryotherapy and COLD Database. In: Focal Therapy of Prostate Cancer: An emerging Strategy for Minimally Invasive, Staged Treatment. Springer International: Switzerland, 99-104, 2015.
2. Ward JF. Energies for Focal Ablation: Cryoablation. In: Focal Therapy in Prostate Cancer. First. Wiley-Blackwell: Hoboken, NJ, 87-97, 2012.
3. Zurita AJ, Ward JF, Kim J. Targeted Therapy in Prostate Cancer. In: Targeted Therapy in Cancer. Humana Press: USA, 289-304, 2008.
4. Rini BJ, Ward JF, Vogelzang NJ. Primary Neoplasms of the Kidney and Renal Pelvis. In: Disease of the Kidney and Urinary Tract. 8th. Lippincott Williams & Wilkins: Philadelphia, PA, 2006.
5. Ward JF, Borboroglu PG. Stones. In: Aging. Salem Press: Pasadena, CA, 719-722, 2000.
6. Ward JF, Bretan PJ. Epitaxy. In: Magill's Survey of Science: Physical Science Series. Salem Press: Pasadena, CA, 2917-2921, 1998.

Letters to the Editor

1. Ward JF, Blute ML. Use and timing of radiotherapy in high-risk prostate cancer. JAMA 291(23): 2817, 2004.
2. Ward JF, Blute ML. Use and timing of radiotherapy in high-risk prostate cancer. JAMA 291(23): 2817, 2004.